BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fiocchi C, Iliopoulos D. What's new in IBD therapy: An "omics network" approach. Pharmacol Res 2020;159:104886. [PMID: 32428668 DOI: 10.1016/j.phrs.2020.104886] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 D'Amico F, Peyrin-Biroulet L, Danese S, Fiorino G. New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming? Curr Opin Pharmacol 2020;55:141-50. [PMID: 33254032 DOI: 10.1016/j.coph.2020.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Cococcioni L, Panelli S, Varotto-boccazzi I, Carlo DD, Pistone D, Leccese G, Zuccotti GV, Comandatore F. IBDs and the pediatric age: Their peculiarities and the involvement of the microbiota. Digestive and Liver Disease 2021;53:17-25. [DOI: 10.1016/j.dld.2020.10.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Nones RB, Fleshner PR, Queiroz NSF, Cheifetz AS, Spinelli A, Danese S, Peyrin-Biroulet L, Papamichael K, Kotze PG. Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. J Clin Med 2021;10:5642. [PMID: 34884344 DOI: 10.3390/jcm10235642] [Reference Citation Analysis]
4 Liu G, Feng S, Sun Y, Wang D, Shao P, Sun P. Colonic macrophage-targeted curcumin nanoparticles alleviate DSS-induced colitis in mice through the NF-kappa B pathway. Food Bioscience 2021;41:101089. [DOI: 10.1016/j.fbio.2021.101089] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Xu M, Kong Y, Chen N, Peng W, Zi R, Jiang M, Zhu J, Wang Y, Yue J, Lv J, Zeng Y, Chin YE. Identification of Immune-Related Gene Signature and Prediction of CeRNA Network in Active Ulcerative Colitis. Front Immunol 2022;13:855645. [PMID: 35392084 DOI: 10.3389/fimmu.2022.855645] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Alsoud D, Vermeire S, Verstockt B. Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises. Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100089] [Reference Citation Analysis]
7 Fiocchi C, Iliopoulos D. Inflammatory Bowel Disease Therapy: Beyond the Immunome. Front Immunol 2022;13:864762. [DOI: 10.3389/fimmu.2022.864762] [Reference Citation Analysis]
8 Guo H, Chi Y, Chi N. Bioinformatis analysis reveals possible molecular mechanism of PXR on regulating ulcerative colitis. Sci Rep 2021;11:5428. [PMID: 33686088 DOI: 10.1038/s41598-021-83742-8] [Reference Citation Analysis]
9 Mishra J, Stubbs M, Kuang L, Vara N, Kumar P, Kumar N, Subramanian VS. Inflammatory Bowel Disease Therapeutics: A Focus on Probiotic Engineering. Mediators of Inflammation 2022;2022:1-15. [DOI: 10.1155/2022/9621668] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
10 Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Reference Citation Analysis]
11 Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol 2021;6:589-95. [PMID: 34019798 DOI: 10.1016/S2468-1253(21)00065-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Damião AOMC, Queiroz NSF. Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough. Clin Colon Rectal Surg 2022;35:032-43. [DOI: 10.1055/s-0041-1740036] [Reference Citation Analysis]
13 Ceballos D. Predictors: How to Approach the Individualization of Treatment. Inflamm Bowel Dis 2021;27:1876-7. [PMID: 34473277 DOI: 10.1093/ibd/izaa228] [Reference Citation Analysis]
14 Gagliardi M, Monzani R, Clemente N, Fusaro L, Saverio V, Grieco G, Pańczyszyn E, Yissachar N, Boccafoschi F, Corazzari M. A Gut-Ex-Vivo System to Study Gut Inflammation Associated to Inflammatory Bowel Disease (IBD). Biology (Basel) 2021;10:605. [PMID: 34209277 DOI: 10.3390/biology10070605] [Reference Citation Analysis]
15 Falloon KA, Fiocchi C. Current Therapy in Inflammatory Bowel Disease: Why and How We Need to Change? EMJ Innov. [DOI: 10.33590/emjinnov/21-00134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Sato M, Fujii K, Takagi H, Shibuya I, Oka D, Yamaya N, Hagita H, Matsumoto M, Inagaki K. Antibacterial and Immunosuppressive Effects of OPS-2071, a Candidate Therapy for Inflammatory Bowel Disease. Dig Dis Sci 2021. [PMID: 34463880 DOI: 10.1007/s10620-021-07237-2] [Reference Citation Analysis]